The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, the Minister for Health has sought the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best practice. The PBAC intends to provide its advice to the Minister at its July 2022 meeting following:
The PBAC will use a two-phased consultation approach to:
Feedback from both phases of the consultation will be considered by the PBAC before it provides it advice.
Timeline
Phase 1 consultation will open from 5 April 2022 and close on 29 April 2022. No extension will be granted.
Phase 2 consultation is expected to occur from 18 May 2022 subject to delivery of the independent analysis and close on 30 May 2022. No extension will be granted.
Any feedback received after the conclusion of the consultation will not be presented to the PBAC for consideration.
Consultation scope
Scope
Out of scope
Phase 1 Questions:
Share
Share on Twitter Share on Facebook